The Cheapest GLP-1 Online in 2026: What You'll Actually Pay After All Fees

Reviewed by FormBlends Medical Team · Last updated September 5, 2026 · 23 sources cited

Key Takeaways

• Compounded semaglutide had a month-one median of $197 across 14 telehealth providers (range $88 to $299) in the Compounded GLP-1 Price Index as of September 3, 2026, but the manufacturers' own self-pay programs now start at $149 (Wegovy pill, Foundayo) and $199 (Ozempic and Wegovy pens for the first two fills), so compounded is no longer automatically the cheapest option
• Brand-name Ozempic and Wegovy retail for about $1,212 and $1,639 a month with no offer (GoodRx, August 2026), but NovoCare Pharmacy sells either pen for $199 a month for a new patient's first two fills and $349 after that through December 31, 2026, and the savings cards bring copays to $25 with commercial insurance
• Hidden fees (consultation charges, shipping, required lab work, subscription minimums) add $50 to $300 to advertised prices across most platforms
• The cheapest option depends on your insurance status: insured patients with savings card eligibility pay less for brand-name, while uninsured patients save 70-85% with compounded alternatives

The short answer

As of September 4, 2026, the cheapest GLP-1 you can get online without insurance is one of three things depending on dose: a $149 starting dose of the Wegovy pill or Foundayo from the manufacturer, a $199 Ozempic or Wegovy pen for the first two months through NovoCare Pharmacy, or compounded semaglutide, which ran a median of $197 in month one across 14 providers in the Compounded GLP-1 Price Index and stays flat while the brand prices step up to $349 and beyond. With commercial insurance and a savings card, brand-name pens cost as little as $25 a month, which beats everything else.

Table of contents

1. The 30-second pricing breakdown
2. What most articles get wrong about "cheapest"
3. Compounded semaglutide vs compounded tirzepatide: actual cost comparison
4. Brand-name vs compounded: the five-scenario decision matrix
5. Hidden fees that inflate advertised prices
6. Platform-by-platform pricing (telehealth comparison table)
7. The insurance paradox: when "free" coverage costs more
8. Walmart, Costco, and retail pharmacy cash prices
9. The FormBlends pricing pattern: what 8,400+ fills reveal
10. When you should NOT choose the cheapest option
11. How to calculate your true monthly cost in 3 steps
12. Manufacturer self-pay prices (September 2026)
13. Brand self-pay vs compounded by dose step
14. Medicare $50 GLP-1 Bridge
15. Cheapest GLP-1 pill
16. Price index snapshot (September 3, 2026)
17. FAQ

The 30-second pricing breakdown

As of September 4, 2026, here's what you'll actually pay per month for GLP-1 medications:

Compounded options (no insurance needed):

• Compounded semaglutide: median $197 in month one and $224 by month four across 14 providers (range $88 to $299), per the FormBlends price index, September 3, 2026
• Compounded tirzepatide: median $299 in month one across 14 providers (range $149 to $470), same source

Brand-name options (manufacturer self-pay, no insurance; retail without an offer in parentheses):

• Ozempic (semaglutide): $199 a month for a new patient's first two fills at NovoCare Pharmacy, then $349 for 0.25 to 1 mg or $499 for 2 mg; Ozempic pill $149, $199 or $299 by strength (about $1,212 retail)
• Wegovy (semaglutide): $199 a month for the first two fills, then $349; Wegovy HD 7.2 mg $399; Wegovy pill $149 for 1.5 mg and 4 mg (4 mg moved to $199 after August 31, 2026), $299 for higher strengths (about $1,639 retail)
• Mounjaro (tirzepatide): $499 a month through Lilly's not-covered savings tier, which requires commercial insurance that does not cover Mounjaro (list price $1,112.16 per 4-pen fill in January 2026; about $1,330 retail per GoodRx)
• Zepbound (tirzepatide) KwikPen through LillyDirect: $299 for 2.5 mg, $399 for 5 mg, $449 for 7.5 mg and above when refilled within 45 days of the prior fill, otherwise $499 for 7.5 mg and $699 for 10 to 15 mg

Brand-name with insurance and savings card:

• As low as $25 per month (commercial insurance only)
• Medicare Part D patients: $50 a month through the Medicare GLP-1 Bridge for Wegovy, Zepbound KwikPen and Foundayo, July 1, 2026 through December 31, 2027, with prior authorization; Ozempic and Mounjaro are not included, and savings cards still do not apply to government plans

The gap between the cheapest self-pay option ($149) and retail Wegovy with no offer (about $1,639) is close to $1,500 a month. Your specific cheapest option depends on three variables: insurance status, diagnosis code, and which dose you end up needing, because the brand self-pay prices step up with dose and compounded prices mostly do not.

What most articles get wrong about "cheapest"

Most price comparison articles commit the same error: they quote advertised platform prices without accounting for mandatory add-ons.

A platform advertising "$199/month semaglutide" typically requires:

• Initial consultation fee: $49 to $99 (sometimes waived, often not)
• Monthly subscription minimum: 3 to 6 months
• Shipping: $0 to $15 per delivery
• Required lab work: $0 to $125 (some platforms bundle, others charge separately)
• Supplies (syringes, alcohol wipes, sharps container): $0 to $35

The true first-month cost for a "$199" platform often lands between $273 and $348. By month three, the average settles to $214 to $230 when amortizing one-time fees.

We analyzed 47 telehealth platforms in Q1 2026. Only 12 disclosed total first-month costs upfront. The average difference between advertised price and actual first-month out-of-pocket was $87.

The second error is ignoring insurance entirely. Articles position compounded semaglutide as universally cheaper, but a patient with commercial insurance and an approved savings card pays $25 monthly for brand-name Ozempic. That's about $170 less than the median compounded month-one price in our index.

The correct question isn't "what's cheapest" but "what's cheapest for my specific insurance and diagnosis situation."

Compounded semaglutide vs compounded tirzepatide: actual cost comparison

Both are compounded GLP-1 medications. Tirzepatide (the active ingredient in Mounjaro and Zepbound) is newer and typically costs $50 to $150 more per month than semaglutide.

Feature	Compounded semaglutide	Compounded tirzepatide
Average monthly cost	$179 to $299	$279 to $449
Typical starting dose cost	$179 to $229	$279 to $349
Maintenance dose cost	$229 to $299	$349 to $449
Injection frequency	Once weekly	Once weekly
Average weight loss at 6 months	12-15% body weight (Wilding et al., NEJM 2021)	15-20% body weight (Jastreboff et al., NEJM 2022)
Nausea incidence	20-44% in trials	25-33% in trials
FDA approval status	Compounded (not FDA-approved)	Compounded (not FDA-approved)

Tirzepatide produces slightly greater average weight loss in head-to-head trials, but the difference is 3-5 percentage points of body weight, not a categorical improvement (Jastreboff et al., NEJM 2022). For a 200-pound patient, that's 6 to 10 additional pounds lost over six months.

The cost-per-pound-lost calculation:

• Semaglutide at $250/month for 15% loss (30 lbs for 200-lb patient): $50 per pound
• Tirzepatide at $400/month for 18% loss (36 lbs): $67 per pound

Semaglutide remains more cost-efficient for most patients. Tirzepatide makes sense when semaglutide produces inadequate response after 16+ weeks at therapeutic dose or when side effects are intolerable.

Brand-name vs compounded: the five-scenario decision matrix

Scenario 1: You have commercial insurance, Ozempic is covered, you qualify for the Novo Nordisk savings card. Cheapest option: Brand-name Ozempic at $25 to $75 per month. Why: The savings card reduces copays below compounded pricing. You get FDA-approved medication with pen convenience.

Scenario 2: You have Medicare or Medicaid. Cheapest option, if you have Part D and meet the criteria: Wegovy, Zepbound KwikPen or Foundayo at $50 a month through the Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027, prior authorization required, and the $50 sits outside the $2,100 Part D cap). If your plan denies the Bridge, or you are on Medicaid in a state that dropped obesity coverage, compounded semaglutide (median $197 in month one) is the fallback. Savings cards never apply to government plans.

Scenario 3: You have no insurance. Cheapest option for the first two months: a $199 Ozempic or Wegovy pen from NovoCare Pharmacy, or a $149 Wegovy pill or Foundayo starting dose. From month three the pens rise to $349 and the pills to $299 at higher strengths, and compounded semaglutide (median $224 by month four) pulls ahead. Brand retail with no offer is $1,212 to $1,639, which nobody should be paying in 2026.

Scenario 4: Your insurance covers GLP-1 for diabetes but not weight loss, and your prescription is for weight management. Cheapest option: the manufacturer self-pay price at your dose (Wegovy pen $199 then $349, Wegovy pill $149 to $299, Zepbound KwikPen $299 to $449) or compounded semaglutide at a median $197 to $224. Insurance denies the off-label claim either way, so compare the self-pay ladder against the price index at the dose you expect to stay on.

Scenario 5: You are on Medicare Part D and your out-of-pocket drug spending is climbing toward the $2,100 cap. The coverage gap no longer exists (it ended with the 2025 Part D redesign), so the question is whether your plan covers the drug at all. Ozempic and Mounjaro for diabetes go through normal Part D cost sharing. For weight management, the $50 Bridge covers Wegovy, Zepbound KwikPen and Foundayo only, and does not count toward the cap. Compounded semaglutide at a median $197 remains the fallback if the Bridge is denied.

The pattern: insurance with savings card eligibility makes brand-name cheapest. Every other scenario favors compounded.

Hidden fees that inflate advertised prices

We surveyed 31 telehealth GLP-1 platforms in March 2026. Here's what the "$199/month" advertised price actually includes and excludes:

Included in advertised price (usually):

• The medication itself
• Prescription from platform provider
• Basic messaging support

Not included (charged separately):

• Initial consultation: $0 to $99 (11 platforms charged, 20 waived with first order)
• Shipping: $0 to $15 (23 platforms included free shipping, 8 charged)
• Syringes and supplies: $0 to $35 (18 platforms included, 13 charged separately or required separate purchase)
• Required lab work: $0 to $125 (9 platforms included, 22 required separate lab orders)
• Subscription commitment: 3 to 6 months minimum (19 platforms required, 12 allowed month-to-month)
• Cancellation fee: $0 to $99 (4 platforms charged early termination fees)

The most deceptive pattern: platforms advertising "$199" that require a $99 consultation, $15 shipping, and $35 supply kit, bringing true first-month cost to $348 (75% higher than advertised).

FormBlends pricing includes consultation, shipping, and basic supplies in the monthly cost. No hidden consultation fees. No mandatory minimums beyond the first month. The advertised price is the out-the-door price.

Platform-by-platform pricing (telehealth comparison table)

The platform-category ranges below were last reviewed in April 2026. For current compounded prices by named provider, checked at checkout each week, use the Compounded GLP-1 Price Index. FormBlends' current price is on the product page and in that index; we do not repeat it here because it changes.

Platform type	Semaglutide (monthly)	Tirzepatide (monthly)	Consultation fee	Shipping	Subscription minimum
FormBlends	See product page and price index	See product page and price index	Included	Included	1 month
Budget telehealth platforms	$199 to $299	$299 to $449	$0 to $49	$0 to $15	3 to 6 months
Premium telehealth platforms	$297 to $499	$399 to $599	Included	Included	1 to 3 months
Local compounding pharmacy (503A)	$150 to $350	$250 to $450	$75 to $150 (separate provider visit)	Pickup only	None
Medical spa / weight loss clinic	$250 to $500	$400 to $700	$100 to $200	N/A (in-person)	Varies widely

Local compounding pharmacies offer the lowest per-dose cost but require a separate provider visit ($75 to $150) and in-person pickup. Total effective monthly cost ends up similar to telehealth once you factor in provider fees and travel.

Medical spas and weight-loss clinics charge the highest prices, often 2x to 3x telehealth rates, justified by in-person monitoring and "concierge" service.

The insurance paradox: when "free" coverage costs more

Here's the counterintuitive scenario we see in about 15% of new patient consultations: a patient has insurance coverage for Ozempic, but paying cash for compounded semaglutide is cheaper.

Example case: Patient has a high-deductible health plan (HDHP) with $5,000 deductible. Ozempic is covered on Tier 3 after deductible. Until the deductible is met, patient pays the negotiated rate: $890 per fill.

If the patient stays on insurance:

• Months 1-5: $890/month (total $4,450 toward deductible)
• Month 6: $890 (deductible met)
• Months 7-12: $150 copay (Tier 3 coinsurance)
• Year 1 total: $5,340 + $900 = $6,240

If the patient switches to compounded semaglutide:

• Months 1-12: $250/month
• Year 1 total: $3,000

The insurance option costs $3,240 more in year one. The patient is paying for "coverage" that makes the medication more expensive.

This pattern appears most often with:

• HDHPs with deductibles above $3,000
• Marketplace plans with high coinsurance (30-40%) on specialty tiers
• Plans that cover GLP-1 only with burdensome prior authorization that delays treatment 4+ weeks

The decision rule: if your insurance requires you to pay more than $300/month out-of-pocket before coverage kicks in, run the math on compounded alternatives.

Walmart, Costco, and retail pharmacy cash prices

For patients who want brand-name medication but don't have insurance, retail pharmacies offer cash pricing. Costco consistently beats other chains by $50 to $150 per fill.

Pharmacy	Ozempic 1mg (1 month)	Wegovy 1.7mg (1 month)	Mounjaro 5mg (1 month)
Walmart	$980 to $1,100	$1,349 to $1,430	$1,023 to $1,150
CVS	$1,025 to $1,150	$1,380 to $1,460	$1,050 to $1,175
Walgreens	$1,040 to $1,165	$1,395 to $1,475	$1,065 to $1,190
Costco (members only)	$895 to $980	$1,280 to $1,350	$920 to $1,025
Sam's Club (members only)	$920 to $1,005	$1,310 to $1,380	$945 to $1,050

Costco membership costs $60 annually. A single fill of Ozempic at Costco vs Walmart saves $85 to $120, paying for the membership in one transaction.

The table above is what retail looked like in April 2026 and it is now mostly irrelevant: as of September 4, 2026, GoodRx's Ozempic page shows Novo Nordisk's own $149 tablet and $199 pen offers at every listed pharmacy instead of a coupon price, against an average retail of $1,212. The manufacturer self-pay price is the same at any participating pharmacy or by home delivery, so shopping chains no longer changes the number.

At the starting doses, brand self-pay ($149 to $199) is now at or below the compounded median. At maintenance doses ($349 for a Wegovy pen, $449 to $699 for Zepbound 7.5 mg and up), brand self-pay runs roughly 1.5x to 3x the compounded median.

The FormBlends pricing pattern: what 8,400+ fills reveal

Across 8,400+ compounded semaglutide fills from July 2024 through March 2026, we see consistent cost patterns:

Starting dose (0.25 mg to 0.5 mg weekly): Average monthly cost: $179 to $229. This dose is typically prescribed for the first 4 to 8 weeks. Patients at this dose are assessing tolerance and early response.

Escalation dose (1 mg to 1.7 mg weekly): Average monthly cost: $229 to $279. About 60% of patients stabilize at this range by week 12 to 16. Weight loss averages 8-12% of starting body weight by month six at this dose.

Maintenance dose (2 mg to 2.4 mg weekly): Average monthly cost: $249 to $299. Roughly 25% of patients escalate to this dose by month six. This group typically includes patients with higher starting BMI (35+) or slower initial response.

High-responder dose (above 2.4 mg weekly): Rare in compounded semaglutide. Most patients who need doses above 2.4 mg switch to tirzepatide, which offers higher ceiling doses (up to 15 mg weekly) with better tolerability at the upper range.

The median patient on compounded semaglutide pays $229 per month by month three and continues at that dose through month 12. Total first-year cost: approximately $2,750 to $3,100 including initial lower-dose months.

Compare that to brand-name Wegovy pens at NovoCare's self-pay price: two months at $199 plus ten at $349, which is $3,888 for the first year (retail with no offer would be about $19,668). At the price index medians, compounded semaglutide comes in near $2,600 for the year, so the annual gap is now closer to $1,300 than the $13,000 an earlier version of this page claimed.

When you should NOT choose the cheapest option

Choosing the cheapest GLP-1 isn't always the right clinical decision. Here are five scenarios where paying more makes sense:

1. You have a strong preference for FDA-approved medications. Compounded semaglutide is not FDA-approved. It's prepared by state-licensed compounding pharmacies under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, but it hasn't undergone the same review process as Ozempic or Wegovy. If FDA approval is a non-negotiable requirement for you, brand-name is worth the premium.

2. You need pen-injector convenience. Brand-name medications come in pre-filled, pre-dosed pens. You twist a dial, inject, done. Compounded semaglutide requires drawing from a vial with a syringe, measuring the dose, and injecting. Most patients adapt within 2 to 3 injections, but some strongly prefer the pen. If you have dexterity issues, vision impairment, or needle anxiety, the pen's ease of use justifies the cost difference.

3. Your insurance copay with savings card is under $100. If you have commercial insurance, your plan covers Ozempic or Wegovy, and the Novo Nordisk or Eli Lilly savings card drops your copay to $25 to $75 per month, that's cheaper than most compounded options. Take the brand-name.

4. You want supply certainty now that the shortages are over. The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. Compounding did not disappear: 503A pharmacies still prepare patient-specific prescriptions, but the shortage-based blanket allowance is gone, and the FDA had logged 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026. If you would rather not depend on how your state board and pharmacy read the current rules, brand-name self-pay removes that variable.

5. You've had prior adverse reactions to compounded medications. Compounded medications use different inactive ingredients (buffers, preservatives, stabilizers) than brand-name formulations. A small percentage of patients react to these excipients. If you have a history of reactions to compounded drugs, brand-name formulations may be safer despite higher cost.

The decision isn't purely financial. Clinical appropriateness, personal preference, and long-term sustainability all factor in.

How to calculate your true monthly cost in 3 steps

Step 1: Determine your insurance status and coverage.

If you have insurance, call the number on your card or log into your member portal. Ask: "Is semaglutide or Ozempic covered on my plan? What tier? What's my copay after deductible?"

If covered with a copay under $150, request a savings card from the manufacturer (Novo Nordisk for Ozempic/Wegovy, Eli Lilly for Mounjaro/Zepbound). Bring both your insurance card and savings card to the pharmacy. The pharmacist will process both and give you the lowest price.

If your copay is over $150 or your plan doesn't cover GLP-1 for your diagnosis, proceed to step 2.

Step 2: Get quotes from 3 to 5 telehealth platforms.

Request a total first-month cost breakdown:

• Medication cost
• Consultation fee (one-time or recurring?)
• Shipping cost
• Supply cost (syringes, alcohol wipes, sharps container)
• Any subscription minimums or cancellation fees

Add these together. This is your true month-one cost.

Ask what the cost becomes in month two and beyond (some platforms waive consultation fees after month one, dropping the recurring cost).

Step 3: Compare total six-month cost.

Multiply month-two-and-beyond cost by 5, add month-one cost. This gives you a realistic six-month total.

Example:

• Month 1: $250 (medication) + $49 (consultation) + $15 (shipping) + $25 (supplies) = $339
• Months 2-6: $250 + $15 = $265 each
• Six-month total: $339 + ($265 x 5) = $1,664

Compare that six-month total across platforms and against your insurance option. The lowest six-month total is your cheapest option, not the lowest advertised monthly price.

Manufacturer self-pay prices as of September 4, 2026: NovoCare Pharmacy and LillyDirect

Both manufacturers now sell direct to uninsured patients at prices that did not exist when this article was first written. Every figure below is posted on the manufacturer's own page and, in each case, stated as valid through December 31, 2026.

Product	Self-pay price per month	Where	Fine print
Ozempic pen	$199 for the first two fills (new patients), then $349 for 0.25, 0.5 and 1 mg or $499 for 2 mg	NovoCare Pharmacy or participating retail pharmacies	Type 2 diabetes prescription; Novo says pricing will be updated after December 31, 2026
Ozempic pill	$149 (1.5 mg), $199 (4 mg), $299 (9 mg)	NovoCare Pharmacy	Same expiry
Wegovy pen	$199 for the first two fills (0.25 and 0.5 mg, new patients through December 31, 2026), then $349; Wegovy HD 7.2 mg $399	NovoCare Pharmacy or retail	Savings card instead: $25 with coverage, maximum $100 a month in savings
Wegovy pill	$149 for 1.5 mg and 4 mg (4 mg became $199 after August 31, 2026); $299 for higher strengths	NovoCare Pharmacy	Retail with no offer about $1,639
Zepbound KwikPen	$299 (2.5 mg), $399 (5 mg), $499 (7.5 mg), $699 (10, 12.5, 15 mg); $449 for any 7.5 mg or higher dose refilled within 45 days of the previous fill	LillyDirect	Expires December 31, 2026
Mounjaro	$499 for a 1-month prescription through Lilly's not-covered tier	Lilly savings program	Requires commercial insurance that does not cover Mounjaro; monthly caps $647 and $8,411 a year per GoodRx's August 2026 write-up; list price $1,112.16 per fill
Foundayo (orforglipron)	$149 for the lowest dose; higher doses cost more	LillyDirect	Approved April 1, 2026 for obesity or overweight with a weight-related condition

Two things to notice. The starting-dose prices are the marketing hook, and every ladder steps up with dose. And none of these programs counts toward an insurance deductible, because you are paying cash outside your plan.

Where compounded stops being cheapest: brand self-pay vs the price index at each dose step

Compounded prices in the Compounded GLP-1 Price Index are mostly flat across the dose ladder (the month-one median was $197 and the month-four median $224 for semaglutide on September 3, 2026, across 14 providers). Brand self-pay is not flat. That crossover is the whole story.

Dose step	Brand self-pay (September 4, 2026)	Compounded median (price index, September 3, 2026)	Cheaper
Semaglutide starting dose, months 1 and 2	$199 pen (Ozempic or Wegovy) or $149 Wegovy pill	$197 semaglutide	Brand, narrowly
Semaglutide maintenance, month 3 onward	$349 pen; $299 pill at higher strengths	$224 semaglutide (month four)	Compounded
Tirzepatide 2.5 mg	$299 Zepbound KwikPen	$299 tirzepatide	Tie
Tirzepatide 5 mg	$399 Zepbound KwikPen	$299 tirzepatide	Compounded
Tirzepatide 7.5 mg and up	$449 with the 45-day refill rule, otherwise $499 to $699	$299 tirzepatide	Compounded by $150 to $400

The practical rule for someone paying cash: start on the brand pen or pill if you want the pen device and FDA-approved product for the two cheap months, then re-price against the index before your third fill. If you expect to need 7.5 mg of tirzepatide or more, compounded is the only option that stays under $300.

Medicare's $50 GLP-1 Bridge (July 1, 2026 to December 31, 2027): who qualifies and which drugs

An earlier version of this page told Medicare patients to expect $200 to $500 copays and go compounded. That advice is out of date. From July 1, 2026 through December 31, 2027, Medicare Part D enrollees (stand-alone Part D or Medicare Advantage with drug coverage) can get three GLP-1 products for $50 a month under the Medicare GLP-1 Bridge, per KFF (May 11, 2026) and healthinsurance.org (August 20, 2026):

• Wegovy, injection or tablet
• Zepbound KwikPen only (Zepbound vials are not included)
• Foundayo (orforglipron) tablets

Ozempic and Mounjaro are not on the list; they remain diabetes drugs under normal Part D cost sharing. The Bridge requires prior authorization with a prescriber attestation of the qualifying diagnosis, and the $50 does not count toward the $2,100 Part D out-of-pocket cap for 2026. Manufacturer savings cards still cannot be used with any government plan. If you are on Medicare and your plan approves the Bridge, $50 beats every compounded price in our index.

Cheapest GLP-1 pill: Foundayo vs Wegovy pill vs Ozempic pill vs Rybelsus

There are now four GLP-1 tablets on the U.S. market, and two of them start at $149.

Pill	Indication	Strengths	Self-pay price (September 4, 2026)
Foundayo (orforglipron), Lilly	Obesity, or overweight with a weight-related condition	0.8, 2.5, 5.5, 9, 14.5, 17.2 mg once daily, no food or water restrictions	$149 for the lowest dose via LillyDirect; $25 with commercial coverage; $50 for eligible Medicare Part D patients from July 1, 2026
Wegovy tablet (semaglutide), Novo Nordisk	Weight management and cardiovascular risk reduction	1.5, 4, 9, 25 mg once daily on an empty stomach	$149 for 1.5 mg (4 mg $199 after August 31, 2026), $299 for higher strengths
Ozempic tablet (semaglutide), Novo Nordisk	Type 2 diabetes	1.5, 4, 9 mg once daily	$149, $199, $299 by strength
Rybelsus (semaglutide), Novo Nordisk	Type 2 diabetes	3, 7, 14 mg once daily	About $1,011 with a GoodRx discount; $10 with the manufacturer copay card and commercial coverage (GoodRx, August 13, 2026)

In Lilly's ATTAIN-1 trial, people on the highest Foundayo dose who stayed on treatment lost an average of 12.4% of body weight (all participants, regardless of completion, 11.1%), per Lilly's April 1, 2026 release. GoodRx's April 6, 2026 comparison summarizes the Wegovy pill trial at about 14% and the Wegovy 2.4 mg injection at about 15%. Cheapest is not the same as most effective, and the pills sit below the injections on weight loss.

What the FormBlends Compounded GLP-1 Price Index showed on September 3, 2026

We publish a checkout-verified index of compounded GLP-1 prices from 14 U.S. telehealth providers, refreshed weekly, at the Compounded GLP-1 Price Index. The September 3, 2026 snapshot:

Product	Month-one median	Range	Month-four median
Compounded semaglutide	$197	$88 to $299	$224
Compounded tirzepatide	$299	$149 to $470	Tracked in the index

The $88 floor and the $470 ceiling are both real checkout prices, and the difference between them is almost entirely plan structure: the lowest numbers are introductory prices tied to 6- or 12-month commitments, and the highest are month-to-month with everything included. Read the plan length before you read the price, which is the same advice the hidden-fees section above has given since April.

FAQ

What is the cheapest GLP-1 medication available online?

It depends on the dose. For the first two months a $149 Wegovy pill or Foundayo starting dose, or a $199 Ozempic or Wegovy pen from NovoCare Pharmacy, is cheapest. After that, compounded semaglutide (median $224 by month four in the FormBlends price index, September 3, 2026) usually undercuts the $349 brand pen price. With commercial insurance and a savings card, brand-name pens are $25 a month.

Is compounded semaglutide as effective as Ozempic?

Compounded semaglutide uses the same active ingredient as Ozempic (semaglutide) but is not FDA-approved and hasn't undergone the same clinical trials. Published data on brand-name semaglutide shows 12-15% average weight loss at six months (Wilding et al., NEJM 2021). Real-world compounded semaglutide outcomes appear similar based on provider reports, but no large-scale trials exist.

Why is compounded semaglutide so much cheaper than Ozempic?

Compounded medications skip the brand-name distribution chain, marketing costs, and patent-protected pricing. A compounding pharmacy makes the medication in response to an individual prescription, reducing overhead. Brand-name Ozempic's price reflects Novo Nordisk's development costs, FDA approval process, and market positioning.

Can I use a GoodRx coupon to make brand-name GLP-1 cheaper?

Not the way it used to. As of September 4, 2026, GoodRx's Ozempic page shows Novo Nordisk's own offers ($149 tablets, $199 pens for the first two fills) at every listed pharmacy rather than a GoodRx coupon price, against an average retail of $1,212. You cannot combine GoodRx with insurance, it's one or the other. GoodRx payments don't count toward your insurance deductible.

Do telehealth platforms accept insurance for compounded GLP-1?

No. Compounded medications are not covered by insurance. Telehealth platforms sell compounded semaglutide and tirzepatide as cash-pay services. You pay out-of-pocket, and the cost doesn't count toward your deductible or out-of-pocket maximum.

What's the difference between 503A and 503B compounding pharmacies?

503A pharmacies compound medications in response to individual patient prescriptions. 503B outsourcing facilities compound larger batches under stricter FDA oversight. Both are legal and state-licensed. FormBlends fills GLP-1 prescriptions through state-licensed 503A compounding pharmacies (Greenwich RX in Texas, The DrugStore on East State in Ohio); Chemistry Rx in Pennsylvania, a 503A and 503B pharmacy, fills other compounded prescriptions.

How long does a vial of compounded semaglutide last?

Most compounded semaglutide vials contain a 4-week supply at your prescribed dose. Some higher-concentration vials last 6 to 8 weeks. Vials must be refrigerated and used within 28 to 60 days after first puncture depending on formulation (check your pharmacy's specific guidance).

Is tirzepatide worth the extra cost over semaglutide?

Tirzepatide produces 3 to 5 percentage points more weight loss on average compared to semaglutide in head-to-head trials (Jastreboff et al., NEJM 2022). For a 200-pound patient, that's 6 to 10 additional pounds over six months. If semaglutide at therapeutic dose produces inadequate response after 16+ weeks, tirzepatide is worth trying. Starting with tirzepatide from day one costs $100 to $200 more monthly without proven benefit for most patients.

Can I switch from brand-name Ozempic to compounded semaglutide mid-treatment?

Yes. The active ingredient is the same. Your provider will convert your current Ozempic dose to the equivalent compounded dose. Most patients switch without interruption. The main adjustment is learning to draw from a vial instead of using a pen.

The FDA shortages ended. Is compounded GLP-1 still allowed?

Both shortages have already ended: the FDA declared tirzepatide resolved on December 19, 2024 and semaglutide resolved on February 21, 2025, with enforcement grace periods that expired in spring 2025. Compounding continues only for patient-specific prescriptions under section 503A, and telehealth providers have adjusted their offerings accordingly. If your state or pharmacy changes its position, the manufacturer self-pay programs ($149 to $349 at most doses through December 31, 2026) are the fallback.

Are there cheaper GLP-1 options coming in 2026 or 2027?

The disruption already happened in 2026: Foundayo (orforglipron), approved April 1, 2026, sells for $149 a month at the lowest dose; the Wegovy pill is $149 for 1.5 mg; and the Ozempic and Wegovy pens are $199 for a new patient's first two fills. Every one of those prices is posted as valid through December 31, 2026, so expect the manufacturers to reset them in January 2027. Generic semaglutide is still years away, and generic liraglutide (Victoza and Saxenda) is the only generic GLP-1 you can buy today.

Does FormBlends offer payment plans or financing?

FormBlends pricing is month-to-month with no long-term contracts. You pay each month as you go. Some patients use HSA/FSA cards (compounded medications are eligible expenses). We don't offer internal financing, but third-party medical financing (CareCredit, etc.) can be used if your provider accepts it.

Who has the cheapest GLP-1 without insurance?

For the first two months, the manufacturers do: Novo Nordisk's NovoCare Pharmacy sells Ozempic and Wegovy pens for $199 a month to new patients and the Wegovy pill for $149, and Lilly sells Foundayo for $149 at the lowest dose (all posted through December 31, 2026, checked September 4, 2026). From month three, compounded semaglutide at a median $224 (FormBlends price index, September 3, 2026) usually wins.

Which GLP-1 is cheapest?

By list of self-pay prices on September 4, 2026: Foundayo and the Wegovy pill at $149 for the starting dose, then Ozempic and Wegovy pens at $199 for two fills, then compounded semaglutide at a $197 month-one median, then Zepbound KwikPen at $299 for 2.5 mg and compounded tirzepatide at a $299 median. Generic liraglutide (Saxenda) is about $372 with a GoodRx discount per GoodRx's August 13, 2026 page.

Where is the cheapest place to get a GLP-1?

The manufacturer pharmacies (NovoCare Pharmacy, LillyDirect) for the introductory brand prices, and a telehealth compounding provider for maintenance doses. Retail chains no longer matter for brand prices: GoodRx showed the same $149 and $199 Novo Nordisk offers at Costco, Walmart, CVS, Walgreens and H-E-B on September 4, 2026. For compounded, compare providers in the FormBlends price index, which is verified at checkout weekly.

Do I need insurance to get a GLP-1?

No. Every product in this article can be bought with a prescription and no insurance: brand pens and pills through the manufacturer self-pay programs ($149 to $699 a month by product and dose, valid through December 31, 2026) and compounded semaglutide or tirzepatide through telehealth (medians $197 and $299 in month one, FormBlends price index, September 3, 2026). Insurance matters only for the $25 savings-card price and the $50 Medicare Bridge.

Related guides

• The Cheapest Online Hormone Replacement Therapy in 2026: What Actually Determines Quality-Adjusted Cost
• What Is the Cheapest Tirzepatide Online Without Insurance in 2026?
• What Are the Cheapest GLP-1 Options in 2026? A Real Price Breakdown
• Will Insurance Cover GLP-1 for Fatty Liver in 2026? What Plans Actually Pay
• Retatrutide Prices in 2026: What You'll Actually Pay for the Triple-Agonist GLP-1
• How to Get a GLP-1 Covered by Insurance: The Prior Authorization Strategy That Actually Works
• Tool: cost calculator

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
4. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. 2024.
5. Eli Lilly. Mounjaro (tirzepatide) Prescribing Information. 2024.
6. GoodRx Research Team. Prior Authorization Survey: GLP-1 Medications. 2024.
7. FDA Drug Shortages Database. Semaglutide and Tirzepatide Shortage Status. Accessed April 2026.
8. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File. 2026.
9. National Association of Boards of Pharmacy. Compounding Pharmacy Regulations: 503A vs 503B. 2025.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
11. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. U.S. Department of Health and Human Services. Federal Poverty Level Guidelines. 2026.
14. American Society of Health-System Pharmacists. Compounding Standards and Regulations. 2025.
15. FormBlends. Compounded GLP-1 Price Index, data as of September 3, 2026. https://formblends.com/report/data/compounded-glp1-price-index
16. Novo Nordisk. What to pay for Wegovy (self-pay pen $199 then $349, HD $399, pill $149), seen September 4, 2026. https://www.wegovy.com/obesity/what-to-pay-for-wegovy.html
17. Novo Nordisk. Wegovy savings card eligibility ($25 with coverage, $100 a month maximum), seen September 4, 2026. https://www.novocare.com/eligibility/wegovy-savings-card.html
18. Novo Nordisk. Ozempic savings offer and NovoCare Pharmacy self-pay prices ($199 first two months, then $349 or $499; pill $149, $199, $299), seen September 4, 2026. https://www.novocare.com/diabetes/products/ozempic/savings-offer.html
19. Eli Lilly. Zepbound coverage and savings (KwikPen self-pay $299 to $699, 45-day $449 rule), seen September 4, 2026. https://zepbound.lilly.com/coverage-savings
20. Eli Lilly. Mounjaro savings and coverage ($499 not-covered price, card caps), 08/2026, seen September 4, 2026. https://mounjaro.lilly.com/savings-coverage
21. GoodRx. How much is Mounjaro without insurance (list price $1,112.16, retail about $1,330, not-covered card caps), August 25, 2026. https://www.goodrx.com/mounjaro/how-much-is-mounjaro-without-insurance
22. GoodRx. Ozempic prices and offers (average retail $1,212), seen September 4, 2026. https://www.goodrx.com/ozempic
23. GoodRx. GLP-1 drugs cost and savings (Rybelsus, generic liraglutide prices), August 13, 2026. https://www.goodrx.com/classes/glp-1-agonists/glp-1-drugs-cost-and-savings
24. GoodRx. GLP-1 drugs comparison (trial weight-loss summaries), April 6, 2026. https://www.goodrx.com/classes/glp-1-agonists/glp-1-drugs-comparison
25. Eli Lilly. FDA approves Foundayo (orforglipron), press release, April 1, 2026. https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html
26. KFF. What to know about the BALANCE model and the Medicare GLP-1 Bridge, May 11, 2026. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
27. healthinsurance.org. Does health insurance cover drugs used for weight loss, August 20, 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
28. U.S. FDA. Declaratory order: resolution of the tirzepatide shortage, December 19, 2024. https://www.fda.gov/media/185577/download
29. U.S. FDA. Declaratory order: resolution of the semaglutide injection shortage, February 21, 2025. https://www.fda.gov/media/185526/download
30. U.S. FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (adverse-event counts as of May 31, 2026). https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Walmart, CVS, Walgreens, Costco, Sam's Club, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.